Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Key Inclusion Criteria: * Provision of signed and dated informed consent form(ICF) * ≥18 years old * Subject diagnosed of AML MRD. * Eastern Cooperative Oncology Group (ECOG) performance status ≤1 * Adequate organ function as defined in the protocol * Donor specific antibody (DSA) to QN-030a: MFI ≤ 2000 Key Exclusion Criteria: * Allergic to drug used in this study * Accept other anti-tumor drug within 2 weeks of day 0 (first QN-030a dose infusion) * Prior allogeneic hematopoietic stem cell transplant (HSCT) within 6 months of Day 0, received systemic immunosuppressive therapy within 7 days of Day 0, or likely to require systemic immunosuppressive therapy * Acute Promyelocytic Leukemia (APL) * Active central nervous system Leukemia. * Uncontrolled, active clinically significant infection * Clinically significant cardiovascular disease as defined in the protocol * History of central nervous system (CNS) disease such as stroke, epilepsy. * Females are pregnant or lactating * Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection * Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject